Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Published on December 18, 2017 at 12:47 pm by Insider Monkey Staff in Hedge Funds

Page 2 of 7

Page 2 of 7 – SEC Filing

1	Names of Reporting Persons. RA Capital Management, LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a) [ ]
	(b) [ ]
3	SEC Use Only
4	Source of Funds (See Instructions): AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e): [ ]
6	Citizenship or Place of Organization. Massachusetts

Number of Shares Beneficially Owned by Each Reporting Person With	7 Sole Voting Power 0
	8 Shared Voting Power 4,588,536
	9 Sole Dispositive Power 0
	10 Shared Dispositive Power 4,588,536

11	Aggregate Amount Beneficially Owned by Each Reporting Person 4,588,536
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]
13	Percent of Class Represented by Amount in Row (11) 19.9%¹
14	Type of Reporting Person (See Instructions) IA, OO (Limited Liability Company)

_________________

¹ Represents 2,428,571 shares
of the common stock (“Common Stock”) of Dicerna Pharmaceuticals, Inc. (the “Issuer”) and 2,159,965 shares
of the Common Stock issuable upon conversion of Preferred Stock (as defined below) which constitute approximately 19.94% of the
class outstanding. The percentage calculation assumes that there are currently 20,848,503 outstanding shares of the Common Stock
of the Issuer, based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2017 as filed with the Securities
and Exchange Commission (“SEC”) on November 2, 2017.

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 2 of 7

NASDAQ:DRNA SEC 13D Filing RA Capital Management Dicerna Pharmaceuticals Inc (DRNA)